Home

Industrial Hot Cell Solution
Safety Work Bench SWB15, for handling of Tc-99m and Ga-68
Facility for Material Testing
Boxes für α/β emitters
Integrated testing devices, e.g. tensile testing
Facility for the production of Tc-99m generators
Hot cell for the research on PET-radiopharmaceuticals

Isotope / Isotopes

Dear Customer,

The COVID-19 pandemic creates unparalleled challenges for all of us. We are re-considering this situation on a day-to-day basis concerning the interests of our customers, suppliers and staff members. Highest priority is on health and safety considerations and preventive measures.

We carry on

Good news first: our measures planned several weeks ago went live and have proven to be effective.

We are available

All our services are up, customers have access to us as usual. Get in contact with us via email or phone. We shall respond. A good deal of our staff members work from their home offices nowadays, thus, the phone landlines are not manned unfortunately. Please send an email to your contact, we shall revert via our mobile phones. Alternatively call our sales team, they are good intermediaries to acquire the required information.

We deliver on schedule

We keep close contact with all our suppliers and service providers, assuring your projects remain on schedule. The same applies to projects and contracts in negotiation. Presently, there are no extraordinary delays in any of these cases. However, we ask for your appreciation when reaction times and call backs might take a bit longer from time to time.

We keep you informed

When we recognize any change in the processing of your project, rest assured you will be informed. Our sales department or the project manager in charge will get in touch with you. While working from a kind of isolation we shall be happy about your call or message.

Please stay well and fit, keep up your perseverance in these difficult times.

Anwendungen / Applications

Hot cells and glove box systems for the safe handling of Alpha- and Beta emitters for therapy

Technology for the production of a wide range of radionuclides for medical or industrial use

Equipment for the production and aseptic dispensing of PET radiopharmaceuticals

Equipment for hot labs ensuring safe manufacturing of radiopharmaceuticals

Complex facilities for special applications of radioactive materials with high requirements regarding process technology and safety

Isotope Technologies Dresden GmbH will be a leading global supplier and integrator of safe, reliable and economical systems to produce radiopharmaceuticals and to handle other radioactive materials.

Based on decades of experience and latest technologies, we contribute to saving lives with our solutions by protecting people, product and the environment.

We provide value to our customers with excellent consultancy service, high quality and life-long technical service.

US-Gesundheitsbehörde bezuschusst MYELO-Strahlenschutzpille mit 6 Mio. USD // US health authorities to provide USD 6 million in funding for MYELO radiation protection pill

Pressemeldung

US-Gesundheitsbehörde bezuschusst MYELO-Strahlenschutzpille mit 6 Mio. USD

Berlin, 11.05.2020. Die Berliner MYELO Therapeutics, ein Beteiligungsunternehmen der Eckert & Ziegler Strahlen- und Medizintechnik AG, erhält von der amerikanischen Gesundheitsbehörde in den nächsten drei Jahren 6 Mio. USD für die Weiterentwicklung seiner Strahlenschutzpille MYELO001. Das Unternehmen setzte sich damit als einer der wenigen europäischen Antragsteller erfolgreich im Wettbewerb um Mittel aus dem relativ generösen US-Katastrophenvorsorgeprogramm durch.

Mit dem Geld sollen weitere Tests und Wirksamkeitsnachweise finanziert und der Funktionsmechanismus des neuen, oral verabreichbaren Medikaments untersucht werden. Sofern die mehrjährigen Prüfungen erfolgreich ausfallen, besteht für MYELO die Chance, von den Katastrophenschutzagenturen in Amerika und anderswo wertvolle Aufträge zur Anlage von Notfallvorräten zu erhalten.

„MYELO Therapeutics gehört zu einer Reihe von strategischen Beteiligungen, mit denen Eckert & Ziegler sein Wachstum mittelfristig in neue Dimensionen voranzutreiben versucht“, erläuterte Dr. Andreas Eckert, Vorstandsvorsitzender des TecDAX-Unternehmens Eckert & Ziegler. „Die Mittel dazu hat der Vorstand in den letzten Jahren kontinuierlich erhöhen können. Zwar wäre es für konkrete Aussagen zu Umsatz- oder Ertragspotenzialen noch Jahre zu früh, der Zuschlag der amerikanischen Gesundheitsbehörde aber zeigt, dass sich Eckert & Ziegler bei der Auswahl ihrer Finanzierungsprojekte auf einem richtigen Weg befindet“.

Zu den Details der Strahlenschutzpille und der Förderzusage der amerikanischen Gesundheitsbehörde siehe die detaillierte Pressemeldung von MYELO Therapeutics: http://www.myelotherapeutics.com/news.html

Über Eckert & Ziegler.
Die Eckert & Ziegler Strahlen- und Medizintechnik AG gehört mit über 800 Mitarbeitern zu den weltweit größten Anbietern von isotopentechnischen Komponenten für Strahlentherapie und Nuklearmedizin. Die Eckert & Ziegler Aktie (ISIN DE0005659700) ist im TecDAX der Deutschen Börse gelistet.
Wir helfen zu heilen.

**********************************************************************************

Press release

US health authorities to provide USD 6 million in funding for MYELO radiation protection pill

Berlin, 11 May 2020. Berlin-based MYELO Therapeutics, an affiliated company of Eckert & Ziegler Strahlen- und Medizintechnik AG, will receive USD 6 million from the National Institutes of Health (NIH) over the next three years for the further development of its radiation protection pill MYELO001. The company is one of the few European applicants to successfully compete for funds from the relatively generous US catastrophe prevention program.

The money will be used to finance further tests and proof of concept and to investigate the functional mechanism of the new orally applicable drug. If the multi-year trials are successful, MYELO has the opportunity to win valuable contracts from civil protection agencies in America and elsewhere to build up emergency stocks.

"MYELO Therapeutics is one of a series of strategic investments that Eckert & Ziegler is using to push its growth into new dimensions in the mid term," explained Dr. Andreas Eckert, CEO of the TecDAX company Eckert & Ziegler. "The Executive Board has been able to continuously increase the financial resources for this purpose over the past few years. Although it would still be years too early to make concrete statements on sales or earnings potential, the award of the contract by the American health authorities shows that Eckert & Ziegler is on the right track when it comes to selecting its financing projects".

For details of the radiation protection pill and the funding commitment of the American health authorities, see the detailed press release of MYELO Therapeutics: http://www.myelotherapeutics.com/news.html

About Eckert & Ziegler.
Eckert & Ziegler Eckert & Ziegler Strahlen- und Medizintechnik AG with more 800 employees, is one of the world's largest providers of isotope-related components for radiation therapy and nuclear medicine. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.